Guardant Health (NASDAQ:GH) Sets New 52-Week High – Should You Buy?

by · The Cerbat Gem

Guardant Health, Inc. (NASDAQ:GH – Get Free Report)’s stock price hit a new 52-week high on Wednesday . The stock traded as high as $105.27 and last traded at $99.35, with a volume of 3391358 shares traded. The stock had previously closed at $95.57.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Guggenheim boosted their price objective on Guardant Health from $56.00 to $67.00 and gave the company a “buy” rating in a report on Thursday, September 25th. Mizuho set a $100.00 price target on shares of Guardant Health in a research report on Thursday, October 30th. Wells Fargo & Company began coverage on shares of Guardant Health in a report on Monday, September 22nd. They set an “overweight” rating and a $72.00 target price for the company. Evercore ISI increased their price target on Guardant Health from $68.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Finally, Barclays boosted their target price on shares of Guardant Health from $70.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $77.14.

Read Our Latest Analysis on Guardant Health

Guardant Health Trading Up 5.1%

The stock’s 50 day moving average is $74.94 and its two-hundred day moving average is $58.51. The stock has a market cap of $13.29 billion, a price-to-earnings ratio of -32.84 and a beta of 1.56.

Guardant Health (NASDAQ:GH – Get Free Report) last announced its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.09. During the same quarter last year, the firm earned ($0.88) earnings per share. The company’s revenue was up 38.5% on a year-over-year basis. Guardant Health has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Insider Activity at Guardant Health

In other news, Director Medina Manuel Hidalgo sold 2,165 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $54.16, for a total transaction of $117,256.40. Following the completion of the sale, the director owned 851 shares of the company’s stock, valued at approximately $46,090.16. This trade represents a 71.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John G. Saia sold 8,996 shares of the business’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $96.25, for a total value of $865,865.00. Following the completion of the sale, the insider directly owned 43,172 shares of the company’s stock, valued at approximately $4,155,305. This represents a 17.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 313,161 shares of company stock valued at $18,996,062. Company insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Guardant Health

A number of institutional investors and hedge funds have recently modified their holdings of GH. Signaturefd LLC grew its stake in Guardant Health by 50.5% during the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after acquiring an additional 213 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Guardant Health by 120.1% during the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after purchasing an additional 334 shares during the last quarter. Allworth Financial LP grew its position in Guardant Health by 358.4% in the 2nd quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after purchasing an additional 552 shares during the last quarter. Sound Income Strategies LLC acquired a new stake in shares of Guardant Health during the 3rd quarter worth approximately $38,000. Finally, Optiver Holding B.V. increased its stake in Guardant Health by 153.5% in the third quarter. Optiver Holding B.V. now owns 768 shares of the company’s stock valued at $48,000 after acquiring an additional 465 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Guardant Health

(Get Free Report)

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Further Reading